Literature DB >> 2347040

The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump.

J A Radford1, J M Margison, R Swindell, M J Lind, P M Wilkinson, N Thatcher.   

Abstract

Dose fractionation is known to reduce the toxicity of ifosfamide and also results in an increased production of alkylating metabolites. Administration by slow infusion using the convenience of ambulatory pumps is therefore of interest. We used HPLC to investigate the stability of ifosfamide in aqueous solution (either alone, solution A, or mixed with mesna, solution B) under various conditions over a 9-day period. At both ambient temperature in daylight and 27 degrees C in a dark environment, there was no evidence of ifosfamide decay in either solution. However, at 37 degrees C in a dark environment, a fall was detected in both solutions, which at 9 days amounted to a loss of 7% of the amount of ifosfamide present at time zero. At 70 degrees C, levels of ifosfamide in both solutions fell within 72 h to markedly lower levels than controls, thus confirming that the methods used were indicative of stability. We conclude that ifosfamide, either alone or mixed with mesna, is stable for 9 days at temperatures up to 27 degrees C; even at 37 degrees C, the measured loss is small. The continuous infusion of ifosfamide over 7 days by ambulatory pump is now a practical proposition.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2347040     DOI: 10.1007/bf02897261

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

Review 1.  Ifosfamide--pharmacology, safety and therapeutic potential.

Authors:  W P Brade; K Herdrich; M Varini
Journal:  Cancer Treat Rev       Date:  1985-03       Impact factor: 12.111

2.  Infusion of ifosphamide plus mesna.

Authors:  I C Shaw; J W Rose
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

3.  Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Cancer Res       Date:  1989-02-01       Impact factor: 12.701

4.  Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.

Authors:  L R Morgan; E F Harrison; J E Hawke; H L Hunter; J J Costanzi; D Plotkin; W G Tucker; P M Worrall
Journal:  Semin Oncol       Date:  1982-12       Impact factor: 4.929

5.  A simple quantitative HPLC assay for ifosfamide in biological fluids.

Authors:  J M Margison; P M Wilkinson; T Cerny; N Thatcher
Journal:  Biomed Chromatogr       Date:  1986-06       Impact factor: 1.902

6.  Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.

Authors:  B M Bryant; M Jarman; H T Ford; I E Smith
Journal:  Lancet       Date:  1980-09-27       Impact factor: 79.321

  6 in total
  5 in total

1.  The stability of mesna in beverages and syrup for oral administration.

Authors:  M P Goren; B A Lyman; J T Li
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 2.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

Review 3.  A review of the stability and compatibility of antineoplastic drugs for multiple-drug infusions.

Authors:  D A Williams; J Lokich
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 4.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

5.  A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer.

Authors:  H Anderson; P Hopwood; J Prendiville; J A Radford; N Thatcher; L Ashcroft
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.